Education and Training
JSP191 Antibody Targeting Conditioning in SCID Patients
A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody conditioning regimen, known as JSP191, in patients with Severe Combined Immune Deficiency undergoing blood stem cell transplantation
Stanford is currently accepting patients for this trial.
Intervention(s):
- biological: Humanized anti-CD117 Monoclonal Antibody (JSP191)
Eligibility
Key Inclusion Criteria:
All patient groups must have:
1. Typical SCID as defined by Primary Immune Deficiency Treatment Consortia including but
not limited to the following subtypes:
1. T-, B+, NK-: IL-2Rcγ deficient, JAK3-deficient
2. T-, B-, NK+: RAG1/2 deficient, Artemis-deficient
3. T-, B+, NK+: IL7Rα deficient, CD3 subunit deficient, CD45 deficient OR Variant
SCID with absent or low T cell function, Omenn syndrome, Leaky SCID, Reticular
dysgenesis, Adenosine deaminase deficiency, and Purine nucleoside phosphorylase
deficiency may be included after consultation with the medical monitor.
2. Patients with human leukocyte antigen (HLA) matched related or unrelated donors
3. Adequate end organ function as defined in study protocol
Key Exclusion Criteria:
1. Patients with any acute or uncontrolled infections
2. Patients receiving any other investigational agents, or concurrent biological,
chemotherapy, or radiation therapy
3. Patients with active malignancies
4. Active GVHD within 6 months prior to enrollment, or on immunosuppressive therapy for
GVHD
Ages Eligible for Study
3 Months - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Elisabeth Merkel, RN
650-721-0644
I'm interested